Cosentyx (Secukinumab) Denied by Insurance

Cosentyx (secukinumab) is an IL-17A inhibitor biologic developed by Novartis, FDA-approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), and enthesitis-related arthritis in pediatric patients. By blocking IL-17A — a cytokine that plays a prominent role in psoriatic and spondyloarthritis inflammation — Cosentyx achieves high rates of skin clearance and joint disease control. Despite its broad approval and well-established safety profile, Cosentyx denials are common, typically driven by step therapy requirements and Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization barriers.

Why Insurance Denies Cosentyx

Step therapy requiring prior biologic failure is the primary barrier, particularly for patients with psoriasis or psoriatic arthritis. Insurers often require documented failure of a conventional systemic therapy (methotrexate, cyclosporine, or apremilast for psoriasis; methotrexate or leflunomide for PsA) before approving any biologic. Some plans add a second step requiring failure of a TNF inhibitor before approving an IL-17 inhibitor like Cosentyx.

Prior authorization is mandatory for all Cosentyx prescriptions. PA criteria vary by indication but generally include: confirmed diagnosis, disease severity assessment (PASI and BSA for psoriasis; joint count and CRP/ESR for PsA and AS), prior treatment documentation, and a physician attestation that Cosentyx is appropriate.

Ankylosing spondylitis and nr-axSpA specific barriers are common because spondyloarthritis is often underdiagnosed and the imaging findings can be subtle. Some insurers require radiographic confirmation of sacroiliitis for AS (modified New York criteria) before approving Cosentyx, and for nr-axSpA they may require specific HLA-B27 testing and MRI evidence of active bone marrow edema. Missing any of these diagnostic elements can result in an automatic denial.

Biosimilar and competitor positioning affect plans that have a preferred alternative biologic — such as an IL-17 inhibitor biosimilar or a competitor IL-17 agent like Taltz — on their formulary. If Cosentyx is not the preferred formulary option, a formulary exception is required before the plan will cover it.

IBD history is a specific contraindication concern. Cosentyx is contraindicated in patients with active inflammatory bowel disease (Crohn's disease or UC), and IL-17 inhibitors are known to worsen IBD. Some insurers flag the IBD contraindication in their PA review. If a patient has a history of IBD in their records, this can trigger an automatic denial that requires explicit clarification that IBD is in remission or resolved.

How to Appeal a Cosentyx Denial

For psoriasis and PsA appeals: Document your PASI/BSA/DLQI scores for psoriasis and your joint count (tender/swollen joints), CRP, and physician global assessment for PsA. Include your full prior treatment history with dates, doses, and reason for discontinuation. If you have prior biologic failure (especially TNF inhibitor failure), provide clinical records from that treatment period.

For ankylosing spondylitis and nr-axSpA appeals: Include your MRI report (showing bone marrow edema at sacroiliac joints for nr-axSpA, or conventional radiograph showing sacroiliitis for AS), HLA-B27 status, ASDAS or BASDAI score, and documentation of NSAID failure (NSAIDs are typically the required first step before any biologic for AS). The ACR and ASAS guidelines recommend TNF inhibitor or IL-17 inhibitor biologics after NSAID failure for active axSpA — cite these guidelines explicitly.

Address the IBD flag proactively. If your records include any historical mention of GI symptoms or IBD, have your gastroenterologist provide a letter confirming that you do not have active IBD or that your IBD history is inactive and not a contraindication to IL-17 therapy.

Challenge step therapy when there is clinical justification to skip. If your physician prefers Cosentyx over a TNF inhibitor as a first biologic — for example, because your disease has a high skin burden where IL-17 inhibitors are superior, or because you have a prior history suggesting better response to IL-17 inhibition — this clinical reasoning should be documented in the medical necessity letter. Some state step therapy laws require exceptions when a preferred drug is clinically inferior for a specific patient's disease profile.

Request peer-to-peer review. Rheumatologists and dermatologists are often able to resolve step therapy overrides in peer-to-peer calls that cannot be resolved through written documentation alone.

Patient Assistance Programs

Novartis offers Cosentyx FollowUp, a patient support and copay assistance program. Commercially insured patients may be eligible for copay assistance reducing out-of-pocket costs significantly. Uninsured or underinsured patients may qualify for free drug through the Novartis Patient Assistance Foundation. Visit cosentyx.com/support or call 1-844-COSENTYX.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?